이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Tharimmune 관리

관리 기준 확인 4/4

Tharimmune's CEO는 Randy Milby, Jan2017 에 임명되었습니다 의 임기는 7.42 년입니다. 총 연간 보상은 $ 742.42K, 50.5% 로 구성됩니다. 50.5% 급여 및 49.5% 보너스(회사 주식 및 옵션 포함). 는 $ 30.94K 가치에 해당하는 회사 주식의 1.33% 직접 소유합니다. 30.94K. 경영진과 이사회의 평균 재임 기간은 각각 3 년과 2.9 년입니다.

주요 정보

Randy Milby

최고 경영자

US$742.4k

총 보상

CEO 급여 비율	50.5%
CEO 임기	7.5yrs
CEO 소유권	1.3%
경영진 평균 재임 기간	3.1yrs
이사회 평균 재임 기간	3yrs

최근 관리 업데이트

Recent updates

Is Hillstream BioPharma (NASDAQ:HILS) In A Good Position To Invest In Growth?

Feb 14

CEO 보상 분석

Randy Milby 의 보수는 Tharimmune 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$9m
Dec 31 2023	US$742k	US$375k	-US$9m
Sep 30 2023	n/a	n/a	-US$9m
Jun 30 2023	n/a	n/a	-US$9m
Mar 31 2023	n/a	n/a	-US$8m
Dec 31 2022	US$3m	US$472k	-US$8m
Sep 30 2022	n/a	n/a	-US$4m
Jun 30 2022	n/a	n/a	-US$3m
Mar 31 2022	n/a	n/a	-US$3m
Dec 31 2021	US$973k	n/a	-US$2m
Sep 30 2021	n/a	n/a	-US$6m
Jun 30 2021	n/a	n/a	-US$6m
Mar 31 2021	n/a	n/a	-US$4m
Dec 31 2020	US$194k	n/a	-US$2m

보상 대 시장: Randy 의 총 보상 ($USD 742.42K )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 683.56K ).

보상과 수익: Randy 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Randy Milby (70 yo)

7.5yrs

테뉴어

US$742,415

보상

Mr. Randy D. Milby, MBA is the Chairman and Chief Executive Officer of Tharimmune, Inc. (formerly known as Hillstream BioPharma, Inc.) since 2017. He is President at Tharimmune, Inc. (formerly known as Hil...

리더십 팀

이름	위치	테뉴어	보상	소유권
Randy Milby	President	7.5yrs	US$742.42k	1.33% $ 34.6k
Sireesh Appajosyula	COO & Director	less than a year	US$602.16k	0.43% $ 11.1k
Thomas Hess	Chief Financial Officer	3.1yrs	데이터 없음	데이터 없음

3.1yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 관리: THAR 의 관리팀은 경험 ( 3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Randy Milby	President	7.5yrs	US$742.42k	1.33% $ 34.6k
Sireesh Appajosyula	COO & Director	3yrs	US$602.16k	0.43% $ 11.1k
Donald W. Kufe	Chair of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Leonard Mazur	Independent Director	3yrs	US$34.43k	0.042% $ 1.1k
Kelly Anderson	Independent Director	1.2yrs	US$46.17k	0% $ 0
Kwok-Kin Wong	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Richard Stone	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Joseph Eder	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Paul Richardson	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Lynne Bui	Independent Director	3yrs	US$41.57k	0% $ 0
Scott Dixon	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Jonathan Rayner	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음

3.0yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: THAR 의 이사회는 경험(평균 재직 기간 3 년)으로 간주됩니다.

Tharimmune 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Tharimmune, Inc., Annual General Meeting, May 14, 2024

Less than half of directors are independent

Hillstream BioPharma, Inc., Annual General Meeting, Aug 08, 2022

No independent directors

Recent updates

Tharimmune, Inc. announced that it has received $2.084162 million in funding from GRAVITAS Capital Advisors, Inc., SDS Capital Group

Tharimmune, Inc. Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, Its Lead Candidate for Moderate-To-Severe Pruritus in Primary Biliary Cholangitis

Tharimmune, Inc. Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-To-Severe Pruritus in Primary Biliary Cholangitis

Tharimmune Announces 1-for-15 Reverse Stock Split, Intends to Bring it into Compliance with Nasdaq's Minimum Bid Price Requirement for Continued Listing

Tharimmune, Inc., Annual General Meeting, May 14, 2024

Tharimmune, Inc. Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate

Tharimmune, Inc. Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis

Tharimmune, Inc. Announces Initiation of Phase 1 Clinical Trial of TH104

Tharimmune, Inc. Announces Positive Topline Data with Th104, Its Lead Candidate for Moderate-To-Severe Pruritus in Chronic Liver Disease Patients

Tharimmune Reports Positive Phase 1 Data on Th104, Its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (Pbc)

Tharimmune, Inc. has completed a Follow-on Equity Offering.

Tharimmune Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market

Tharimmune, Inc. has filed a Follow-on Equity Offering.

Hillstream Biopharma Progressing Towards Acquiring Clinical Stage Asset

New major risk - Shareholder dilution

Less than half of directors are independent

Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2 HER3 Solid Tumors Via Bispecific and ADC Antibodies and Biologics

Hillstream Biopharma Receives Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Hillstream BioPharma, Inc. announced delayed 10-Q filing

Hillstream BioPharma Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Is Hillstream BioPharma (NASDAQ:HILS) In A Good Position To Invest In Growth?

Hillstream BioPharma, Inc. Announces Initial Results Evaluating the Synergy

Hillstream BioPharma, Inc. Announces Acceptance of Abstract At AACR 2023 Annual Meeting Highlighting HSB-510 as Novel Bi-Functional Inhibitor for Solid Tumors & Leukemias

Hillstream BioPharma, Inc. to Host Virtual R&D Day to Showcase Its Emerging Immuno-Oncology Pipeline Targeting Drug-Resistant Cancers

Hillstream BioPharma Receives Non-Compliance Written Notice from the Nasdaq

Hillstream BioPharma, Inc., Annual General Meeting, Aug 08, 2022

Hillstream BioPharma, Inc. (NasdaqCM:HILS) announces an Equity Buyback for $1 million worth of its shares.

Hillstream BioPharma, Inc. announced delayed annual 10-K filing

Hillstream BioPharma, Inc. has completed an IPO in the amount of $15 million.

No independent directors

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령